Survival of patients with mucinous ovarian carcinoma and ovarian metastases: A population-based cancer registry study

International Journal of Gynecological Cancer

Volumn 25, Issue 7, 2015, Pages 1208-1215

  Simons, Michiel ^a   Ezendam, Nicole ^b,c   Bulten, Johan ^a   Nagtegaal, Iris ^a   Massuger, Leon ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Eindhoven Cancer Registry   (Netherlands)

^c TILBURG UNIVERSITY   (Netherlands)

Author keywords

Metastasis; Mucinous ovarian carcinoma; Ovarian cancer; Survival

Indexed keywords

ADJUVANT CHEMOTHERAPY; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER PATIENT; CANCER PROGNOSIS; CANCER REGISTRY; CANCER SURVIVAL; CLEAR CELL CARCINOMA; CYTOREDUCTIVE SURGERY; ENDOMETRIOID CARCINOMA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MUCINOUS OVARIAN CARCINOMA; MULTIMODALITY CANCER THERAPY; OVARY ADENOCARCINOMA; OVARY CARCINOMA; OVARY METASTASIS; OVERALL SURVIVAL; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME; ADENOCARCINOMA, MUCINOUS; AGED; CANCER STAGING; CYSTADENOCARCINOMA, SEROUS; FOLLOW UP; MIDDLE AGED; MORTALITY; NETHERLANDS; OVARIAN NEOPLASMS; PATHOLOGY; PROGNOSIS; REGISTER;

ADENOCARCINOMA, MUCINOUS; AGED; CYSTADENOCARCINOMA, SEROUS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; NETHERLANDS; OVARIAN NEOPLASMS; PROGNOSIS; REGISTRIES; SURVIVAL RATE;

EID: 84940950621     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0000000000000473     Document Type: Article

References (24)

1. Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9-29.
2. Chen T, Jansen L, Gondos A, et al. Survival of ovarian cancer patients in Germany in the early 21st century: a period analysis by age, histology, laterality, and stage. Eur J Cancer Prev. 2013;22:59-67.
3. Schiavone MB, Herzog TJ, Lewin SN, et al. Natural history and outcome of mucinous carcinoma of the ovary. Am J Obstet Gynecol. 2011;205:480.e1-480.e8.
4. Hess V, A'Hern R, Nasiri N, et al. Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment. J Clin Oncol. 2004;22:1040-1044.
5. Winter WE 3rd, Maxwell GL, Tian C, et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007;25:3621-3627.
6. Hart WR. Diagnostic challenge of secondary (metastatic) ovarian tumors simulating primary endometrioid and mucinous neoplasms. Pathol Int. 2005;55:231-243.
7. Harrison ML, Jameson C, Gore ME. Mucinous ovarian cancer. Int J Gynecol Cancer. 2008;18:209-214.
8. Fritz A, Percy C, Jack A, et al. International Classification of Diseases for Oncology (ICD-O-3). 3rd ed. Geneva, Switzerland: WHO Press; 2000.
9. Seidman JD, Kurman RJ, Ronnett BM. Primary and metastatic mucinous adenocarcinomas in the ovaries: incidence in routine practice with a new approach to improve intraoperative diagnosis. Am J Surg Pathol. 2003;27:985-993.
10. Khunamornpong S, Suprasert P, Pojchamarnwiputh S, et al. Primary and metastatic mucinous adenocarc inomas of the ovary: evaluation of the diagnostic approach using tumor size and laterality. Gynecol Oncol. 2006;101:152-157.
11. Kelemen LE, Kobel M. Mucinous carcinomas of the ovary and colorectum: different organ, same dilemma. Lancet Oncol. 2011;12:1071-1080.
12. Kobel M, Kalloger SE, Huntsman DG, et al. Differences in tumor type in low-stage versus high-stage ovarian carcinomas. Int J Gynecol Pathol. 2010;29:203-211.
13. Kondi-Pafiti A, Kairi-Vasilatou E, Iavazzo C, et al. Metastatic neoplasms of the ovaries: a clinicopathological study of 97 cases. Arch Gynecol Obstet. 2011;284:1283-1288.
14. de Waal YR, Thomas CM, Oei AL, et al. Secondary ovarian malignancies: frequency, origin, and characteristics. Int J Gynecol Cancer. 2009;19:1160-1165.
15. Yada-HashimotoN,YamamotoT,KamiuraS, et al. Metastatic ovarian tumors: a review of 64 cases. Gynecol Oncol. 2003;89:314-317.
16. Pectasides D, Fountzilas G, Aravantinos G, et al. Advanced stage mucinous epithelial ovarian can cer: the Hellenic Cooperative Oncology Group experience. Gynecol Oncol. 2005;97:436-441.
17. Bamias A, Psaltopoulou T, Sotiropoulou M, et al. Mucinous but not clear cell histology is associated w ith inferior survival in patients with advanced stage ovarian carcinoma treated with platinum-paclitaxel chemotherapy. Cancer. 2010;116:1462-1468.
18. Bristow RE,Tomacruz RS,Armstrong DK,et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-Analysis J Clin Oncol. 2002, 20, 1248-1259.
19. van der Burg ME, van Lent M, Buyse M, et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med. 1995;332:629-634.
20. Le T, Krepart GV, Lotocki RJ, et al. Does debulking surgery improve survival in biologically aggressive ovarian carcinoma? Gynecol Oncol. 1997;67:208-214.
21. du Bois A, Reuss A, Pujade-Lauraine E, et al. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsg emeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer. 2009;115:1234-1244.
22. Chang SJ, Bristow RE, Ryu HS. Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer. Ann Surg Oncol. 2012;19:4059-4067.
23. Peiretti M, Zanagnolo V, Aletti GD, et al. Role of maximal primary cytoreductive surgery in patients with advanced epithelial ovarian and tubal cancer: surgical and oncological outcomes. Single institution experience. Gynecol Oncol. 2010;119:259-264.
24. Luyckx M, Leblanc E, Filleron T, et al. Maximal cytoreduction in patients with FIGO stage IIIC to stage IV ovarian, fallopian, and peritoneal cancer in day-to-da y practice: a Retrospective French Multicentric Study. Int J Gynecol Cancer. 2012;22:1337-1343.